SOURCE: Brower Piven, A Professional Corporation

July 13, 2011 17:50 ET

Brower Piven Encourages Investors Who Have Losses in Excess of $300,000 From Investment in BioMimetic Therapeutics, Inc. to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the September 6, 2011 Lead Plaintiff Deadline

STEVENSON, MD--(Marketwire - Jul 13, 2011) - Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Middle District of Tennessee on behalf of purchasers of the securities of BioMimetic Therapeutics, Inc. ("BioMimetic" or the "Company") (NASDAQ: BMTI) during the period between October 14, 2009 and May 11, 2011, inclusive (the "Class Period").

No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff no later than September 6, 2011 and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement and how much of a settlement to accept for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the Company during the Class Period. You are not required to have sold your shares to seek damages or to serve as a Lead Plaintiff.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the Company's failure to disclose during the Class Period full and accurate information regarding the status of ongoing clinical studies status of Augment™ Bone Graft ("Augment") and regarding the safety and efficacy of Augment. According to the complaint, after, on May 10, 2011, the FDA published briefing documents that were a scathing assessment of the conduct of the Augment clinical trial, the value of BioMimetic shares declined significantly.

If you have suffered a net loss for all transactions in BioMimetic Therapeutics, Inc. securities during the Class Period (including shares or possibly calls purchased during, but not sold until after the end of the Class Period or possibly put options sold but not covered until after the end of the Class Period), you may obtain additional information about this lawsuit and your ability to become a lead plaintiff by contacting Brower Piven at, by email at, by calling 410/415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined experience litigating securities and class action cases of over 60 years. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.

Contact Information

    Charles J. Piven
    Brower Piven, A Professional Corporation
    Stevenson, Maryland
    Email Contact